Stock Market Reviews

Read and share opinions on ACTU (Actuate Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
  Sep 22, 2025
• Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
  Sep 11, 2025
• Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
  Sep 10, 2025
• Actuate Therapeutics Announces Proposed Public Offering of Common Stock
  Sep 9, 2025
• Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20%
  Aug 15, 2025
• Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
  Aug 6, 2025
• Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
  Jun 24, 2025
• Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
  Jun 20, 2025
• Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
  Jun 16, 2025
• Actuate Therapeutics shares highlights from KOL eventon elraglusib data
  Jun 3, 2025
• Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
  Jun 2, 2025
• Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
  May 31, 2025
• Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
  May 22, 2025
• Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
  May 7, 2025
• Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
  Apr 30, 2025